BridgeBio Oncology Therapeutics, Inc. Operating Cash Flow
BridgeBio Oncology Therapeutics, Inc. (BBOT) reported Operating Cash Flow of -$80.28 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-11
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$44.36M.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$35.92M.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$42.23M.
- BridgeBio Oncology Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$28.77M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$44.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$80.28M 10-Q · filed 2026-08-11 | -$122.51M derived: sum of 3 quarters · filed 2026-08-11 | -$151.28M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2026-03-31 | -$35.92M 10-Q · filed 2026-05-12 | -$78.15M derived: sum of 2 quarters · filed 2026-05-12 | -$106.92M derived: sum of 3 quarters · filed 2026-05-12 | -$130.21M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-12-31 | -$42.23M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | -$71.00M derived: sum of 2 quarters · filed 2026-04-30 | -$94.30M derived: sum of 3 quarters · filed 2026-08-11 | -$113.89M POS AM · filed 2026-04-30 | ||||
| 2025-09-30 | -$28.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$52.06M derived: sum of 2 quarters · filed 2026-08-11 | -$71.66M 10-Q · filed 2025-11-12 | -$86.69M derived: sum of 4 quarters · filed 2026-08-11 | ||||
| 2025-06-30 | -$23.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$42.89M 10-Q · filed 2026-08-11 | -$1.03M 10-Q · filed 2025-08-01 | -$57.93M derived: sum of 3 quarters · filed 2026-08-11 | -$97.27M derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | -$19.60M 10-Q · filed 2026-05-12 | -$734.64K 10-Q · filed 2025-05-15 | -$34.63M derived: sum of 2 quarters · filed 2026-05-12 | -$73.98M derived: sum of 3 quarters · filed 2026-05-12 | -$74.01M derived: sum of 4 quarters · filed 2026-05-12 | |||
| 2024-12-31 | -$15.04M derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-30 | -$54.38M derived: sum of 2 quarters · filed 2026-04-30 | -$54.41M derived: sum of 3 quarters · filed 2026-04-30 | -$55.03M POS AM · filed 2026-04-30 | -$763.82K 10-K · filed 2025-03-11 | |||
| 2024-09-30 | -$39.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$39.37M derived: sum of 2 quarters · filed 2025-11-12 | -$39.99M 10-Q · filed 2025-11-12 | -$675.96K 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | -$29.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-01 | -$647.10K 10-Q · filed 2025-08-01 | ||||||
| 2024-03-31 | -$618.00K 10-Q · filed 2025-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |